You've just started the Wegovy 0.5 mg pen — here's what to expect

You're on your second pen, and wondering if anything should feel different

Picture this: four weeks in, your 0.25 mg pen is finished, and the 0.5 mg pen has arrived. You've felt something, maybe a little nausea after the first couple of injections, maybe not much at all. Now the dose is doubling and you're not sure what that means.

It means you're exactly where the prescribing schedule intends you to be. The 0.25 mg starting pen is a tolerability step: its job is to let your gut adapt to semaglutide, not to drive weight loss. The 0.5 mg pen continues that work, and at this stage the medicine is still building towards the doses that carry the clinical evidence for meaningful weight reduction. Expecting the scales to move dramatically at 0.5 mg sets you up for unnecessary disappointment.

What you might notice is that appetite begins to feel slightly different, a little less urgent, perhaps a fuller feeling after smaller meals. Some people report this clearly; others barely register it. Both are normal. The titration process is not a race, and a slow, steady step-up is linked to better tolerability over the months ahead. If you want a fuller picture of the whole schedule, the Wegovy dose guide walks through each step in detail.

Why the 0.5 mg pen sits where it does in the schedule

Semaglutide works by activating GLP-1 receptors in the gut and brain, slowing how quickly the stomach empties and signalling fullness earlier in a meal. That's powerful, but it's also why starting too high causes nausea, vomiting and other gastrointestinal upset in a significant proportion of patients.

The graduated schedule (0.25 mg, then 0.5 mg, then stepping up roughly every four weeks through 1.0 mg, 1.7 mg and on to 2.4 mg maintenance) exists specifically to smooth that curve. The Wegovy overview covers the full pharmacology, but the short version is this: each step gives your gut receptors time to settle before the next increase. Skipping or rushing steps doesn't speed up results; it raises the chance of side effects severe enough to put people off continuing.

The NHS patient information for semaglutide confirms this stepped approach and notes that gastrointestinal effects are most common after starting the medicine or after a dose increase, typically easing within a matter of days. You can read the NHS semaglutide patient information for the full side-effect and storage detail.

One practical note on timing: if your pen delivery falls over a bank holiday or you're travelling, a short delay of a day or two in taking your weekly injection is manageable, but speak to your prescriber if you're unsure. Missing a dose and what to do next is worth reading up on before it happens.

Side effects at 0.5 mg, what's common, what to watch for

The side-effect profile at 0.5 mg is similar to 0.25 mg but can feel a little more pronounced for some people. Nausea is the most frequently reported complaint, followed by constipation, diarrhoea, indigestion and burping. Headache and fatigue crop up too. Most of these settle without any change to the dose.

Practical things that genuinely help: injecting in the evening so any nausea passes overnight, staying well hydrated, eating smaller portions and avoiding very fatty or rich meals around injection day. These aren't rigid rules, they're the kind of adjustments that our prescribers hear patients mention most often as making the early weeks easier.

There are symptoms that should prompt urgent medical attention regardless of when they appear. Severe, persistent stomach pain that spreads towards your back (with or without vomiting) warrants a same-day call to your GP or 111. The MHRA highlighted acute pancreatitis as a known, if uncommon, serious side effect of GLP-1 medicines in a 2026 Drug Safety Update; it is rare, but the symptom pattern is specific enough to act on promptly. Signs of a serious allergic reaction, gallbladder pain, or symptoms of dehydration from prolonged vomiting or diarrhoea also need prompt assessment.

If you experience something unexpected and want to report it, the MHRA Yellow Card scheme lets patients report suspected side effects directly. Your prescriber should also know.

What comes after the 0.5 mg pen

After four weeks at 0.5 mg, the next step is the 1.0 mg dose. From there the schedule continues upward toward 1.7 mg and then 2.4 mg, which has been the standard maintenance dose in the clinical trials that established Wegovy's weight-loss evidence, including the STEP 1 trial, which reported an average weight reduction of around 15% over 68 weeks at 2.4 mg. In January 2026 the MHRA also approved a 7.2 mg maintenance dose, available as a dedicated single-dose pen, for adults with a BMI of 30 or above, which trials suggested could bring average losses closer to 20%.

The 1 mg pen page covers what to expect at that next step, including how the injection technique stays the same and what changes in terms of side-effect likelihood. If you're wondering about the practical side of injection (rotating sites, the 30-minute morning timing for the oral option, or storage) the guide to using the 0.5 mg pen has the detail.

Reaching 2.4 mg is a clinical process, not a foregone conclusion. If side effects at any dose are difficult to manage, your prescriber may slow the titration or hold the dose steady for longer. The schedule is a framework, not a fixed contract. If you're accessing Wegovy privately and want that kind of ongoing prescriber oversight built in from the start, starting a free consultation gives you a named clinician reviewing your progress at every step.